---
document_datetime: 2025-12-02 05:01:21
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/inhixa.html
document_name: inhixa.html
version: success
processing_time: 0.1214597
conversion_datetime: 2025-12-24 01:31:28.146312
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Inhixa

[RSS](/en/individual-human-medicine.xml/66104)

##### Authorised

This medicine is authorised for use in the European Union

enoxaparin sodium Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Inhixa](#news-on)
- [Related content](#related-content-614)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Inhixa is an anticoagulant medicine (a medicine that prevents blood clots) used in adults for:

• preventing venous thromboembolism (blood clots that form inside the veins, obstructing blood flow), especially in patients who are having surgery or who are at greater risk of clots because they are beridden due to illness;

• treating deep vein thrombosis (DVT, where the clot develops in a deep vein, usually in the leg) and pulmonary embolism (PE, a clot in a blood vessels supplying the lungs);

• treating DVT and PE in patients with active cancers, and preventing these clotting problems from occurring again;

• treating unstable angina (a severe type of chest pain caused by problems with the blood flow to the heart);

• treating certain types of myocardial infarction (heart attack);

• preventing clots forming when blood is circulated through a haemodialysis machine to remove toxic substances. In the treatment of unstable angina and heart attack Inhixa is given with aspirin (acetylsalicylic acid).

Inhixa contains the active substance enoxaparin sodium and is a 'biosimilar medicine'. This means that Inhixa is highly similar to another biological medicine (the 'reference medicine') that is already authorised in the EU. The reference medicine for Inhixa is Clexane. For more information on biosimilar medicines, see here.

Expand section

Collapse section

## How is Inhixa used?

Inhixa is usually given as an injection under the skin although in the treatment of a type of heart attack called acute ST-segment elevation myocardial infarction (STEMI) it is first given as an injection into a vein, and to prevent clots in haemodialysis machines it is injected directly into the tube carrying the blood. The dose and how long the medicine is given for, as well as whether it is given with other medicines, depend on the condition to be prevented or treated. Doses must be adjusted in patients with severely reduced kidney function.

The medicine can only be obtained with a prescription. For more information about using Inhixa, see the package leaflet or contact your doctor or pharmacist.

## How does Inhixa work?

When blood clots develop inside blood vessels they may restrict the blood flow to the organs, including the heart. The active substance in Inhixa, enoxaparin, is one of a group of anticoagulant medicines called low-molecular weight heparins. Enoxaparin increases the effect of antithrombin III, a natural substance that controls the blood's clotting factors and helps prevent blood from clotting inside the body. This helps to stop the formation of new blood clots and control existing ones.

## What benefits of Inhixa have been shown in studies?

Laboratory studies comparing Inhixa with Clexane have shown that the active substance in Inhixa is highly similar to that in Clexane in terms of structure, purity and biological activity.

In addition, a study in 20 healthy subjects has shown that the same doses of the two products given by injection under the skin produced similar effects on blood clotting factors, using various measures that reflect the way the medicine works in the body.

The company also provided information from published studies showing the benefits of enoxaparin in preventing and treating blood clots.

Because Inhixa is a biosimilar medicine, the studies on effectiveness and safety of enoxaparin carried out with Clexane do not all need to be repeated for Inhixa.

## What are the risks associated with Inhixa?

The safety of Inhixa has been evaluated, and on the basis of all the studies carried out the side effects of the medicine are considered to be comparable to those of the reference medicine Clexane

.The most common side effect with Inhixa (which may affect more than 1 in 10 people) is haemorrhage (bleeding); serious bleeding may occur in around 4 in 100 people given Inhixa to prevent blood clots during surgery. In addition, increased levels of liver enzymes in the blood (a sign of possible liver problems) are very common (may affect more than 1 in 10 people).

For the full list of side effects reported with Inhixa, see the package leaflet.

Inhixa must not be used in patients with existing major bleeding, severe disorders of blood clotting, or with conditions that increase the risk of, or from, bleeding, such as stomach ulcers or stroke. For the full list of restrictions, see the package leaflet.

## Why is Inhixa authorised in the EU?

The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Inhixa has a highly similar structure, purity and biological activity to Clexane, and has the same effect on blood clotting factors. The safety profiles of the two medicines were also considered similar, based on laboratory testing.

All these data were considered sufficient to conclude that Inhixa will behave in the same way as Clexane in terms of effectiveness and safety in its authorised uses. Therefore, the Agency's view was that, as for Clexane, the benefits of Inhixa outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Inhixa?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Inhixa have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Inhixa are continuously monitored. Suspected side effects reported with Inhixa are carefully evaluated and any necessary action taken to protect patients.

## Other information about Inhixa

Inhixa received a marketing authorisation valid throughout the EU on 15 September 2016.

This overview was last updated in 04-2022.

Inhixa : EPAR - Summary for the public

Reference Number: EMA/33241/2022

English (EN) (142.71 KB - PDF)

**First published:** 26/10/2016

**Last updated:** 06/09/2022

[View](/en/documents/overview/inhixa-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-775)

български (BG) (166.72 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

06/09/2022

[View](/bg/documents/overview/inhixa-epar-summary-public_bg.pdf)

español (ES) (144.13 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

06/09/2022

[View](/es/documents/overview/inhixa-epar-summary-public_es.pdf)

čeština (CS) (165.94 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

06/09/2022

[View](/cs/documents/overview/inhixa-epar-summary-public_cs.pdf)

dansk (DA) (141.72 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

06/09/2022

[View](/da/documents/overview/inhixa-epar-summary-public_da.pdf)

Deutsch (DE) (146.11 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

06/09/2022

[View](/de/documents/overview/inhixa-epar-summary-public_de.pdf)

eesti keel (ET) (129.97 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

06/09/2022

[View](/et/documents/overview/inhixa-epar-summary-public_et.pdf)

ελληνικά (EL) (165.62 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

06/09/2022

[View](/el/documents/overview/inhixa-epar-summary-public_el.pdf)

français (FR) (144.37 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

06/09/2022

[View](/fr/documents/overview/inhixa-epar-summary-public_fr.pdf)

hrvatski (HR) (157.51 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

06/09/2022

[View](/hr/documents/overview/inhixa-epar-summary-public_hr.pdf)

italiano (IT) (141.87 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

06/09/2022

[View](/it/documents/overview/inhixa-epar-summary-public_it.pdf)

latviešu valoda (LV) (178.85 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

06/09/2022

[View](/lv/documents/overview/inhixa-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (165.62 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

06/09/2022

[View](/lt/documents/overview/inhixa-epar-summary-public_lt.pdf)

magyar (HU) (159.75 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

06/09/2022

[View](/hu/documents/overview/inhixa-epar-summary-public_hu.pdf)

Malti (MT) (166.84 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

06/09/2022

[View](/mt/documents/overview/inhixa-epar-summary-public_mt.pdf)

Nederlands (NL) (142.48 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

06/09/2022

[View](/nl/documents/overview/inhixa-epar-summary-public_nl.pdf)

polski (PL) (166.75 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

06/09/2022

[View](/pl/documents/overview/inhixa-epar-summary-public_pl.pdf)

português (PT) (143.89 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

06/09/2022

[View](/pt/documents/overview/inhixa-epar-summary-public_pt.pdf)

română (RO) (162.07 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

06/09/2022

[View](/ro/documents/overview/inhixa-epar-summary-public_ro.pdf)

slovenčina (SK) (166.92 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

06/09/2022

[View](/sk/documents/overview/inhixa-epar-summary-public_sk.pdf)

slovenščina (SL) (161.89 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

06/09/2022

[View](/sl/documents/overview/inhixa-epar-summary-public_sl.pdf)

Suomi (FI) (134.01 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

06/09/2022

[View](/fi/documents/overview/inhixa-epar-summary-public_fi.pdf)

svenska (SV) (140.87 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

06/09/2022

[View](/sv/documents/overview/inhixa-epar-summary-public_sv.pdf)

Inhixa : EPAR - Risk-management-plan summary

English (EN) (205.53 KB - PDF)

**First published:** 04/01/2022

[View](/en/documents/rmp-summary/inhixa-epar-risk-management-plan-summary_en.pdf)

## Product information

Inhixa : EPAR - Product information

English (EN) (3.25 MB - PDF)

**First published:** 26/10/2016

**Last updated:** 18/11/2025

[View](/en/documents/product-information/inhixa-epar-product-information_en.pdf)

[Other languages (23)](#file-language-dropdown-540)

български (BG) (3.98 MB - PDF)

**First published:**

26/10/2016

**Last updated:**

18/11/2025

[View](/bg/documents/product-information/inhixa-epar-product-information_bg.pdf)

español (ES) (3.58 MB - PDF)

**First published:**

26/10/2016

**Last updated:**

18/11/2025

[View](/es/documents/product-information/inhixa-epar-product-information_es.pdf)

dansk (DA) (3.42 MB - PDF)

**First published:**

26/10/2016

**Last updated:**

18/11/2025

[View](/da/documents/product-information/inhixa-epar-product-information_da.pdf)

Deutsch (DE) (3.81 MB - PDF)

**First published:**

26/10/2016

**Last updated:**

18/11/2025

[View](/de/documents/product-information/inhixa-epar-product-information_de.pdf)

eesti keel (ET) (3.31 MB - PDF)

**First published:**

26/10/2016

**Last updated:**

18/11/2025

[View](/et/documents/product-information/inhixa-epar-product-information_et.pdf)

ελληνικά (EL) (4.45 MB - PDF)

**First published:**

26/10/2016

**Last updated:**

18/11/2025

[View](/el/documents/product-information/inhixa-epar-product-information_el.pdf)

français (FR) (4.15 MB - PDF)

**First published:**

26/10/2016

**Last updated:**

18/11/2025

[View](/fr/documents/product-information/inhixa-epar-product-information_fr.pdf)

hrvatski (HR) (3.83 MB - PDF)

**First published:**

26/10/2016

**Last updated:**

18/11/2025

[View](/hr/documents/product-information/inhixa-epar-product-information_hr.pdf)

íslenska (IS) (3.49 MB - PDF)

**First published:**

26/10/2016

**Last updated:**

18/11/2025

[View](/is/documents/product-information/inhixa-epar-product-information_is.pdf)

italiano (IT) (4.2 MB - PDF)

**First published:**

26/10/2016

**Last updated:**

18/11/2025

[View](/it/documents/product-information/inhixa-epar-product-information_it.pdf)

latviešu valoda (LV) (3.97 MB - PDF)

**First published:**

26/10/2016

**Last updated:**

18/11/2025

[View](/lv/documents/product-information/inhixa-epar-product-information_lv.pdf)

lietuvių kalba (LT) (4.05 MB - PDF)

**First published:**

26/10/2016

**Last updated:**

18/11/2025

[View](/lt/documents/product-information/inhixa-epar-product-information_lt.pdf)

magyar (HU) (4.02 MB - PDF)

**First published:**

26/10/2016

**Last updated:**

18/11/2025

[View](/hu/documents/product-information/inhixa-epar-product-information_hu.pdf)

Malti (MT) (4.55 MB - PDF)

**First published:**

26/10/2016

**Last updated:**

18/11/2025

[View](/mt/documents/product-information/inhixa-epar-product-information_mt.pdf)

Nederlands (NL) (3.76 MB - PDF)

**First published:**

26/10/2016

**Last updated:**

18/11/2025

[View](/nl/documents/product-information/inhixa-epar-product-information_nl.pdf)

norsk (NO) (3.31 MB - PDF)

**First published:**

26/10/2016

**Last updated:**

18/11/2025

[View](/no/documents/product-information/inhixa-epar-product-information_no.pdf)

polski (PL) (4.19 MB - PDF)

**First published:**

26/10/2016

**Last updated:**

18/11/2025

[View](/pl/documents/product-information/inhixa-epar-product-information_pl.pdf)

português (PT) (3.53 MB - PDF)

**First published:**

26/10/2016

**Last updated:**

18/11/2025

[View](/pt/documents/product-information/inhixa-epar-product-information_pt.pdf)

română (RO) (4.17 MB - PDF)

**First published:**

26/10/2016

**Last updated:**

18/11/2025

[View](/ro/documents/product-information/inhixa-epar-product-information_ro.pdf)

slovenčina (SK) (4.01 MB - PDF)

**First published:**

26/10/2016

**Last updated:**

18/11/2025

[View](/sk/documents/product-information/inhixa-epar-product-information_sk.pdf)

slovenščina (SL) (3.87 MB - PDF)

**First published:**

26/10/2016

**Last updated:**

18/11/2025

[View](/sl/documents/product-information/inhixa-epar-product-information_sl.pdf)

Suomi (FI) (3.63 MB - PDF)

**First published:**

26/10/2016

**Last updated:**

18/11/2025

[View](/fi/documents/product-information/inhixa-epar-product-information_fi.pdf)

svenska (SV) (3.44 MB - PDF)

**First published:**

26/10/2016

**Last updated:**

18/11/2025

[View](/sv/documents/product-information/inhixa-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000303314 15/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Inhixa : EPAR - All Authorised presentations

English (EN) (269.43 KB - PDF)

**First published:** 26/10/2016

**Last updated:** 27/06/2024

[View](/en/documents/all-authorised-presentations/inhixa-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-111)

български (BG) (189.35 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

27/06/2024

[View](/bg/documents/all-authorised-presentations/inhixa-epar-all-authorised-presentations_bg.pdf)

español (ES) (192.13 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

27/06/2024

[View](/es/documents/all-authorised-presentations/inhixa-epar-all-authorised-presentations_es.pdf)

čeština (CS) (212.77 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

27/06/2024

[View](/cs/documents/all-authorised-presentations/inhixa-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (196.4 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

27/06/2024

[View](/da/documents/all-authorised-presentations/inhixa-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (186.6 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

27/06/2024

[View](/de/documents/all-authorised-presentations/inhixa-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (188.14 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

27/06/2024

[View](/et/documents/all-authorised-presentations/inhixa-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (203.17 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

27/06/2024

[View](/el/documents/all-authorised-presentations/inhixa-epar-all-authorised-presentations_el.pdf)

français (FR) (194.17 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

27/06/2024

[View](/fr/documents/all-authorised-presentations/inhixa-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (201.89 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

27/06/2024

[View](/hr/documents/all-authorised-presentations/inhixa-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (182.35 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

27/06/2024

[View](/is/documents/all-authorised-presentations/inhixa-epar-all-authorised-presentations_is.pdf)

italiano (IT) (185.05 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

27/06/2024

[View](/it/documents/all-authorised-presentations/inhixa-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (184.94 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

27/06/2024

[View](/lv/documents/all-authorised-presentations/inhixa-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (190.63 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

27/06/2024

[View](/lt/documents/all-authorised-presentations/inhixa-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (190.08 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

27/06/2024

[View](/hu/documents/all-authorised-presentations/inhixa-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (208.44 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

27/06/2024

[View](/mt/documents/all-authorised-presentations/inhixa-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (182.28 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

27/06/2024

[View](/nl/documents/all-authorised-presentations/inhixa-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (196.46 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

27/06/2024

[View](/no/documents/all-authorised-presentations/inhixa-epar-all-authorised-presentations_no.pdf)

polski (PL) (203.16 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

27/06/2024

[View](/pl/documents/all-authorised-presentations/inhixa-epar-all-authorised-presentations_pl.pdf)

português (PT) (193.58 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

27/06/2024

[View](/pt/documents/all-authorised-presentations/inhixa-epar-all-authorised-presentations_pt.pdf)

română (RO) (197.75 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

27/06/2024

[View](/ro/documents/all-authorised-presentations/inhixa-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (192.31 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

27/06/2024

[View](/sk/documents/all-authorised-presentations/inhixa-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (187.24 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

27/06/2024

[View](/sl/documents/all-authorised-presentations/inhixa-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (184.74 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

27/06/2024

[View](/fi/documents/all-authorised-presentations/inhixa-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (194.24 KB - PDF)

**First published:**

26/10/2016

**Last updated:**

27/06/2024

[View](/sv/documents/all-authorised-presentations/inhixa-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Inhixa Active substance enoxaparin sodium International non-proprietary name (INN) or common name enoxaparin sodium Therapeutic area (MeSH) Venous Thromboembolism Anatomical therapeutic chemical (ATC) code B01AB05

### Pharmacotherapeutic group

Antithrombotic agents

### Therapeutic indication

Inhixa is indicated for adults for:

- Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery.
- Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL).
- Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism.
- Treatment of unstable angina and non Q wave myocardial infarction, in combination with acetylsalicylic acid (ASA).
- Treatment of acute ST segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL).
- Blood clot prevention in the extracorporeal circulation during haemodialysis.

## Authorisation details

EMA product number EMEA/H/C/004264

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Techdow Pharma Netherlands B.V.

Strawinskylaan 1143, Toren C-11

Opinion adopted 21/07/2016 Marketing authorisation issued 15/09/2016 Revision 30

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Inhixa : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (153.74 KB - PDF)

**First published:** 23/05/2025

**Last updated:** 18/11/2025

[View](/en/documents/procedural-steps-after/inhixa-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Inhixa : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (251.51 KB - PDF)

**First published:** 08/02/2017

**Last updated:** 23/05/2025

[View](/en/documents/procedural-steps-after/inhixa-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Inhixa-H-C-PSUSA-00010833-202104 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/617395/2021

English (EN) (129.35 KB - PDF)

**First published:** 19/01/2022

[View](/en/documents/scientific-conclusion/inhixa-h-c-psusa-00010833-202104-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Inhixa : EPAR - Public assessment report

Adopted

Reference Number: EMA/536977/2016

English (EN) (998.65 KB - PDF)

**First published:** 26/10/2016

**Last updated:** 26/10/2016

[View](/en/documents/assessment-report/inhixa-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Inhixa

Adopted

Reference Number: EMA/CHMP/482423/2016

English (EN) (70.05 KB - PDF)

**First published:** 22/07/2016

**Last updated:** 22/07/2016

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-inhixa_en.pdf)

#### News on Inhixa

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2016) 22/07/2016

#### Related content

- [Biosimilar medicines](/en/human-regulatory/overview/biosimilar-medicines)
- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC0042640000) (initial marketing authorisation)

#### Topics

- [Biosimilars](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A45)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 18/11/2025

## Share this page

[Back to top](#main-content)